Document is current
Any future updates will be listed below
-
Authors
Shanmugam, Sri Karthika https://orcid.org/0000-0002-1467-401X
Kanner, Scott A.
Zou, Xinle
Amarh, Enoch https://orcid.org/0009-0009-7307-5613
Choudhury, Papiya
Soni, Rajesh https://orcid.org/0000-0002-4556-4358
Kass, Robert S.
Colecraft, Henry M. https://orcid.org/0000-0002-2340-8899
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (RO1 HL121253, RO1 HL142111, P01 HL164319, 1F30 HL140878)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01 NS126850)
American Heart Association (POST1019343)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM007367)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA013696, S10RR027050)
- License Information
-
More Information
Article History
Received: 28 October 2024
Accepted: 7 June 2025
First Online: 1 July 2025
Competing interests
: S.A.K. and H.M.C. are inventors on a patent held by Columbia University for “Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes.” H.M.C. is a scientific co-founder and on the SAB of two startups, Stablix, Inc. and Flux Therapeutics, pursuing targeted protein stabilization therapeutics. S.A.K. is a co-founder and employee of Stablix, Inc. The remaining authors declare no competing interests.
